Key Documents
Kristen Ganjoo
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Oncology
- Member, Cancer Center
Contact Information
-
Clinical Offices
Medical Oncology 875 Blake Wilbur Dr Clinic B MC 5820 Stanford, CA 94305-5820 Tel Work (650) 498-6000 Fax (650) 725-9113
- Academic Offices
Personal Information EmailAdministrative Contact Email Tel Work 650-493-5000Not for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Cancer > Lymphoma
- Cancer > Medical Oncology
- Hodgkin's Disease
- Hodgkin's Disease - Hematology
- Hodgkin's Disease - Medical Oncology
Administrative Appointments
- Assistant Professor of Medicine, Stanford University (2004 - present)
- Assistant Professor of Medicine, Indiana University (2000 - 2004)
Professional Education
| Board Certification: | Oncology, American Board of Internal Medicine (2000) |
| Fellowship: | Indiana University School Of Medicine, IN (2000) |
| Residency: | Indiana University, IN (1997) |
| Internship: | Indiana University, IN (1995) |
| Medical Education: | University of South Alabama Medical Center, AL (1994) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information
| Consulting: | On Speakers Bureau for GSK and Genentech |
Scientific Focus
Research Interests
Clinical research with new and novel therapies for lymphomas and sarcomas including anti-angiogenesis agents and hypoxia activating agents.
Clinical Trials
- Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma Recruiting
- SARC 009: A Phase II Trial of Dasatinib in Advanced Sarcomas Recruiting
- A Pivotal Open-Label Trial of SGN-35 for Hodgkin Lymphoma Recruiting
- A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Second-Line Treatment of Patients With DLBCL Recruiting
- Clinical Trial of PXD101 in Patients With T-Cell Lymphomas Recruiting
Publications
- Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec. Leuk Lymphoma. 2009; (11): 1882-4
- Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy. Leuk Lymphoma. 2009; (4): 673-5
- (131)I-Tositumomab (Bexxar(R)) vs. (90)Y-Ibritumomab (Zevalin(R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma. Mol Imaging Biol. 2009
- Trabectedin: an anticancer drug from the sea. Expert Opin Pharmacother. 2009; (16): 2735-43
- Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol. 2009; (6): 2347-56
Help